ozogamicin

Ozogamicin is a drug linker used for antibody-drug conjugates (ADCs). Ozogamicin can be utilized in the synthesis of drugs such as Gemtuzumab ozogamicin.

Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a CD33-specific monoclonal antibody linked to a cytotoxic agent derived from Calicheamicin, utilized in the investigation of acute myeloid leukemia [1].

Inotuzumab Ozogamicin is an antibody-conjugated active molecule (ADC) that targets CD22 and is conjugated to Ozogamicin, a cytotoxic antibiotic. Inotuzumab Ozogamicin is indicated for use in the study of acute lymphoblastic leukemia (ALL).

Gemtuzumab(CMA-676) is a monoclonal antibody directed against the CD33 antigen and consists of a recombinant humanized IgG4 antibody.Gemtuzumab can be used to synthesize Gemtuzumab ozogamicin, an antibody coupled compound (ADC) Gemtuzumab is used in the study of acute myeloid leukemia.

Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22. This naked antibody can be used to synthesize antibody-active molecule conjugators [Inotuzumab ozogamicin] and to study acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

AcBut, a cleavable linker utilized in the synthesis of Ozogamicin, facilitates the production of agent-linker conjugates for antibody-drug conjugates (ADC) [1].